Detalles de la búsqueda
1.
Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals.
PLoS Pathog
; 19(11): e1011744, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37910480
2.
In-solution buffer-free digestion allows full-sequence coverage and complete characterization of post-translational modifications of the receptor-binding domain of SARS-CoV-2 in a single ESI-MS spectrum.
Anal Bioanal Chem
; 413(30): 7559-7585, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34739558
3.
Expanding the Scope of Ugi Multicomponent Bioconjugation to Produce Pneumococcal Multivalent Glycoconjugates as Vaccine Candidates.
Bioconjug Chem
; 31(9): 2231-2240, 2020 09 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-32809806
4.
Influence of the Co-Administration of Heptavalent Conjugate Vaccine PCV7-TT on the Immunological Response Elicited by VA-MENGOC-BC® and Heberpenta®-L in Rabbits.
Immunol Invest
; 46(4): 395-408, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28379053
5.
Vaccination Achievements of Cuba Versus the United States Exposed by the 2019 Measles Epidemic.
Am J Public Health
; 110(4): 467-469, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32159983
6.
Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2-11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study.
Lancet Reg Health Am
; 34: 100750, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38699214
7.
Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine.
Heliyon
; 9(10): e20555, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37810803
8.
Comparative Immune Response after Vaccination with SOBERANA® 02 and SOBERANA® plus Heterologous Scheme and Natural Infection in Young Children.
Vaccines (Basel)
; 11(11)2023 Oct 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38005968
9.
Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial.
JAMA Netw Open
; 6(5): e2310302, 2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37133864
10.
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial.
Lancet Reg Health Am
; 18: 100423, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36618081
11.
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children.
Int J Infect Dis
; 126: 164-173, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36403819
12.
Quantitative proton magnetic resonance determination of N,N-dimethylformamide in one intermediate of the Quimi-Hib vaccine.
Magn Reson Chem
; 50(8): 525-8, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22730256
13.
Repeat-dose and local tolerance toxicity of SARS-CoV-2 FINLAY-FR-02 vaccine candidate in Sprague Dawley rats.
Toxicology
; 471: 153161, 2022 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35364223
14.
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.
Vaccine
; 40(13): 2068-2075, 2022 03 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35164986
15.
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial.
Lancet Respir Med
; 10(8): 785-795, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35691295
16.
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults.
Med
; 3(11): 760-773.e5, 2022 11 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35998623
17.
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
Vaccine
; 40(31): 4220-4230, 2022 07 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-35691871
18.
A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles.
RSC Chem Biol
; 3(2): 242-249, 2022 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35360883
19.
Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines.
ACS Cent Sci
; 7(5): 757-767, 2021 May 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34075345
20.
Glycan Array Evaluation of Synthetic Epitopes between the Capsular Polysaccharides from Streptococcus pneumoniae 19F and 19A.
ACS Chem Biol
; 16(9): 1671-1679, 2021 09 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-34469105